Does the media prefer SKYE or ATRA?

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 2 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.37 beat Atara Biotherapeutics' score of -0.07 indicating that Skye Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SKYE or GANX more profitable?

Gain Therapeutics' return on equity of -201.44% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% Gain Therapeutics N/A -201.44% -136.24%

Does the media favor SKYE or GANX?

In the previous week, Skye Bioscience and Skye Bioscience both had 2 articles in the media. Gain Therapeutics' average media sentiment score of 0.53 beat Skye Bioscience's score of 0.37 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IBIO or SKYE more profitable?

iBio's return on equity of -53.86% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Skye Bioscience N/A -217.27% -162.39%

Does the media refer more to IBIO or SKYE?

In the previous week, iBio had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 3 mentions for iBio and 2 mentions for Skye Bioscience. iBio's average media sentiment score of 0.60 beat Skye Bioscience's score of 0.37 indicating that iBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate XBIT or SKYE?

Skye Bioscience has a consensus price target of $8.50, indicating a potential upside of 1,491.76%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, XBIT or SKYE?

XBiotech is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.32 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is XBIT or SKYE more profitable?

XBiotech's return on equity of -26.10% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% Skye Bioscience N/A -217.27% -162.39%

Which has stronger valuation & earnings, CYPH or SKYE?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is CYPH or SKYE more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -48.33% -42.21% Skye Bioscience N/A -217.27% -162.39%

Does the media refer more to CYPH or SKYE?

In the previous week, Skye Bioscience had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Skye Bioscience and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Skye Bioscience's score of 0.37 indicating that Cypherpunk Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Skye Bioscience (SKYE) Competitors

$0.53 +0.01 (+2.81%)

As of 11:33 AM Eastern

Compare

SKYE vs. ATRA, GANX, IBIO, XBIT, and CYPH

Should you buy Skye Bioscience stock or one of its competitors? MarketBeat compares Skye Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Skye Bioscience include Atara Biotherapeutics (ATRA), Gain Therapeutics (GANX), iBio (IBIO), XBiotech (XBIT), and Cypherpunk Technologies (CYPH). These companies are all part of the "biotechnology" industry.

How does Skye Bioscience compare to Atara Biotherapeutics?

Skye Bioscience (NASDAQ:SKYE) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Skye Bioscience has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Atara Biotherapeutics has higher revenue and earnings than Skye Bioscience. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Atara Biotherapeutics	$23.14M	3.26	$32.69M	-$0.67	N/A

Skye Bioscience has a beta of 2.97, suggesting that its share price is 197% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market.

Skye Bioscience currently has a consensus price target of $8.50, suggesting a potential upside of 1,491.76%. Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential upside of 13.64%. Given Skye Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Skye Bioscience is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 2 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.37 beat Atara Biotherapeutics' score of -0.07 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Skye Bioscience and Atara Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Skye Bioscience compare to Gain Therapeutics?

Skye Bioscience (NASDAQ:SKYE) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Gain Therapeutics has higher revenue and earnings than Skye Bioscience. Gain Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Gain Therapeutics	$50K	1,514.08	-$20.16M	-$0.58	N/A

Gain Therapeutics' return on equity of -201.44% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Gain Therapeutics	N/A	-201.44%	-136.24%

Skye Bioscience has a beta of 2.97, indicating that its share price is 197% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

Skye Bioscience presently has a consensus price target of $8.50, indicating a potential upside of 1,491.76%. Gain Therapeutics has a consensus price target of $7.50, indicating a potential upside of 322.54%. Given Skye Bioscience's higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Skye Bioscience and Skye Bioscience both had 2 articles in the media. Gain Therapeutics' average media sentiment score of 0.53 beat Skye Bioscience's score of 0.37 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gain Therapeutics beats Skye Bioscience on 8 of the 14 factors compared between the two stocks.

How does Skye Bioscience compare to iBio?

iBio (NASDAQ:IBIO) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

iBio has higher revenue and earnings than Skye Bioscience. iBio is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	175.74	-$18.38M	-$0.58	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

iBio's return on equity of -53.86% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Skye Bioscience	N/A	-217.27%	-162.39%

iBio has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.97, meaning that its share price is 197% more volatile than the broader market.

iBio presently has a consensus target price of $5.00, suggesting a potential upside of 253.36%. Skye Bioscience has a consensus target price of $8.50, suggesting a potential upside of 1,491.76%. Given Skye Bioscience's higher probable upside, analysts clearly believe Skye Bioscience is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

7.9% of iBio shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 2.8% of iBio shares are held by insiders. Comparatively, 6.2% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, iBio had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 3 mentions for iBio and 2 mentions for Skye Bioscience. iBio's average media sentiment score of 0.60 beat Skye Bioscience's score of 0.37 indicating that iBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Skye Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

iBio beats Skye Bioscience on 10 of the 15 factors compared between the two stocks.

How does Skye Bioscience compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

XBiotech's return on equity of -26.10% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Skye Bioscience	N/A	-217.27%	-162.39%

XBiotech is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

Skye Bioscience has a consensus price target of $8.50, indicating a potential upside of 1,491.76%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Skye Bioscience had 2 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Skye Bioscience and 0 mentions for XBiotech. Skye Bioscience's average media sentiment score of 0.37 beat XBiotech's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
XBiotech	Neutral
Skye Bioscience	Neutral

XBiotech has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.97, indicating that its stock price is 197% more volatile than the broader market.

Summary

Skye Bioscience beats XBiotech on 8 of the 14 factors compared between the two stocks.

How does Skye Bioscience compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

Cypherpunk Technologies presently has a consensus target price of $0.90, indicating a potential upside of 30.95%. Skye Bioscience has a consensus target price of $8.50, indicating a potential upside of 1,491.76%. Given Skye Bioscience's higher possible upside, analysts plainly believe Skye Bioscience is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Skye Bioscience had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Skye Bioscience and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Skye Bioscience's score of 0.37 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Skye Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cypherpunk Technologies has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.97, meaning that its stock price is 197% more volatile than the broader market.

Cypherpunk Technologies' return on equity of -48.33% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Skye Bioscience	N/A	-217.27%	-162.39%

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cypherpunk Technologies and Skye Bioscience tied by winning 6 of the 12 factors compared between the two stocks.

Get Skye Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SKYE vs. The Competition

Export

Metric	Skye Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.77M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.37	9.06	269.91	24.87
Price / Sales	N/A	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.86	17.97	11.40	6.45
Net Income	-$55.92M	-$13.25M	$3.45B	$347.50M
7 Day Performance	-8.59%	5.58%	3.66%	3.77%
1 Month Performance	-22.61%	-1.60%	-0.49%	-0.40%
1 Year Performance	-84.83%	61.32%	77.51%	23.55%

Skye Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SKYE Skye Bioscience	2.0453 of 5 stars	$0.53 +2.8%	$8.50 +1,491.8%	-85.2%	$18.77M	N/A	N/A	11
ATRA Atara Biotherapeutics	1.3123 of 5 stars	$8.77 +2.6%	$9.50 +8.3%	-22.8%	$77.04M	$120.77M	N/A	330	News Coverage Analyst Downgrade
GANX Gain Therapeutics	2.2437 of 5 stars	$1.76 +0.6%	$7.50 +326.1%	+23.0%	$74.64M	$50K	N/A	20	News Coverage Positive News Upcoming Earnings
IBIO iBio	2.5299 of 5 stars	$1.46 +2.8%	$5.00 +242.5%	N/A	$70.54M	$300K	N/A	100
XBIT XBiotech	0.3679 of 5 stars	$2.24 +0.4%	N/A	-22.3%	$68.14M	N/A	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SKYE) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Skye Bioscience (SKYE) Competitors

SKYE vs. ATRA, GANX, IBIO, XBIT, and CYPH

How does Skye Bioscience compare to Atara Biotherapeutics?

Summary

How does Skye Bioscience compare to Gain Therapeutics?

Summary

How does Skye Bioscience compare to iBio?

Summary

How does Skye Bioscience compare to XBiotech?

Summary

How does Skye Bioscience compare to Cypherpunk Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Skye Bioscience (SKYE) Competitors

SKYE vs. ATRA, GANX, IBIO, XBIT, and CYPH

How does Skye Bioscience compare to Atara Biotherapeutics?

Is SKYE or ATRA more profitable?

Which has better valuation & earnings, SKYE or ATRA?

Which has more risk & volatility, SKYE or ATRA?

Do analysts prefer SKYE or ATRA?

Does the media prefer SKYE or ATRA?

Do institutionals and insiders hold more shares of SKYE or ATRA?

Summary

How does Skye Bioscience compare to Gain Therapeutics?

Which has stronger earnings and valuation, SKYE or GANX?

Is SKYE or GANX more profitable?

Which has more volatility and risk, SKYE or GANX?

Do analysts rate SKYE or GANX?

Do institutionals and insiders have more ownership in SKYE or GANX?

Does the media favor SKYE or GANX?

Summary

How does Skye Bioscience compare to iBio?

Which has higher valuation and earnings, IBIO or SKYE?

Is IBIO or SKYE more profitable?

Which has more volatility & risk, IBIO or SKYE?

Do analysts prefer IBIO or SKYE?

Do institutionals and insiders believe in IBIO or SKYE?

Does the media refer more to IBIO or SKYE?

Summary

How does Skye Bioscience compare to XBiotech?

Is XBIT or SKYE more profitable?

Which has preferable earnings & valuation, XBIT or SKYE?

Do analysts rate XBIT or SKYE?

Do insiders & institutionals have more ownership in XBIT or SKYE?

Does the media favor XBIT or SKYE?

Which has more risk and volatility, XBIT or SKYE?

Summary

How does Skye Bioscience compare to Cypherpunk Technologies?

Which has stronger valuation & earnings, CYPH or SKYE?

Do analysts prefer CYPH or SKYE?

Does the media refer more to CYPH or SKYE?

Which has more risk & volatility, CYPH or SKYE?

Is CYPH or SKYE more profitable?

Do insiders & institutionals believe in CYPH or SKYE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools